Enovis (ENOV) vs Establishment Labs (ESTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Establishment Labs (ESTA) has outperformed Enovis (ENOV) over the past year, gaining 53.7% versus a loss of 43.6%. Over five years, ESTA leads with a -19.9% price change compared with -79.7% for ENOV. Establishment Labs is the larger company by market cap ($1.84 billion vs $1.02 billion), about 1.8 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 1027.8x for Establishment Labs). Establishment Labs converts more of its revenue into profit, with a net margin of -24.2% versus -52.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | ESTA |
|---|---|---|
| Share price | $17.69 | $61.67 |
| Market cap | $1.02B | $1.84B |
| 1-day change | +1.49% | +1.75% |
| YTD return | -33.60% | -15.38% |
| 1-year return | -43.61% | +53.71% |
| 5-year return | -79.70% | -19.91% |
| Forward P/E | 4.93 | — |
| EPS (TTM) | $-19.23 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.25B | $211.08M |
| Revenue growth (YoY) | +6.66% | +27.14% |
| Net income (latest FY) | $-1.18B | $-51.06M |
| Gross margin | 59.84% | 69.32% |
| Operating margin | -50.01% | -18.48% |
| Net margin | -52.69% | -24.19% |
| 52-week high | $34.28 | $97.59 |
| 52-week low | $16.70 | $38.38 |
| Distance from 52-week high | -48.40% | -36.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.44% | +66.11% |
| Average volume | 1.46M | 427.13K |
| Shares outstanding | 57.67M | 29.80M |
| Employees | 7,802 | 1,004 |
| Sector | Health Care | Healthcare |
| Industry | Industrial Specialties | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESTA has outperformed ENOV by 97.3 percentage points over the past year.
- Establishment Labs is more profitable, keeping -24.2 cents of every revenue dollar as net income versus -52.7 cents for Enovis.
- Establishment Labs grew revenue faster in its latest fiscal year (+27.14% vs +6.66%).
- The two companies sit in different sectors: Enovis in Health Care and Establishment Labs in Healthcare.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Healthcare · Medical Devices · 1,004 employees
ENOV vs ESTA FAQ
Which is bigger, Enovis or Establishment Labs?
Establishment Labs (ESTA) is larger, with a market capitalization of $1.84B compared with $1.02B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or ESTA?
ESTA returned +53.71% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Enovis and Establishment Labs in the same industry?
No. Enovis is in the Health Care sector, while Establishment Labs is in Healthcare.